MEDICO.BO Medico Remedies BSE up 19.75% pre-market Jan 24 2026: watch INR 62.22
MEDICO.BO stock jumped 19.75% in pre-market trade on Jan 24, 2026, trading at INR 53.53 after opening at INR 50.99. The move came on a volume spike to 48,776 shares, nearly 2.82x the average volume of 12,580, signalling heavy buyer interest. For traders focused on top gainers, Medico Remedies Limited (MEDICO.BO) on the BSE shows a clear short-term momentum shift, but fundamentals and upcoming earnings on Feb 3, 2026, should govern follow-through. We unpack price action, ratios, technicals, Meyka AI grading, and model forecasts to frame trading and investment scenarios.
Pre-market move and key quote for MEDICO.BO stock
Medico Remedies (MEDICO.BO) opened at INR 50.99 and hit a pre-market high of INR 54.08 before settling at INR 53.53, a +19.75% intraday rise. Volume reached 48,776 versus an average of 12,580, giving a relative volume of 2.82. The day low was INR 48.34 and the previous close was INR 44.70. This rapid move places MEDICO.BO among top gainers on the BSE in early trade and demands attention to short-term liquidity and stop levels.
Fundamentals snapshot: valuation and profitability
Medico Remedies reports EPS INR 1.37 and a trailing P/E of 35.89, with market cap at roughly INR 4,080,323,280.00. Price-to-sales stands at 2.38 and price-to-book is 6.11. Return on equity is 18.35% and net profit margin is 6.61%. Current ratio is 1.62 and debt-to-equity is 0.19, showing modest leverage. These figures show profitability but elevated valuation multiples versus peers in the healthcare sector.
Technicals and trading signals for short-term traders
Technical indicators show mixed signals. RSI sits at 37.41, below neutral, while MACD is negative with histogram -0.33, suggesting limited trend strength. Bollinger Bands middle is INR 50.41 with upper band INR 53.71; price at INR 53.53 is near the upper band. On-balance volume is 80,060, supporting buying flow. Average 50-day price is INR 50.69 and 200-day is INR 48.15, so recent price exceeds both averages, hinting at short-term bullish momentum despite weak momentum oscillators.
Meyka AI grades MEDICO.BO: score, reasoning and analyst frame
Meyka AI rates MEDICO.BO with a score of 64.56 out of 100 — Grade B, Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade balances solid ROE and low leverage against high P/B and stretched P/E. These grades are not guaranteed and we are not financial advisors. For full context, see the Medico profile and peer comparisons on Investing.com source.
Meyka AI forecast model projects and implied moves
Meyka AI’s forecast model projects a monthly target INR 62.22, quarterly INR 48.23, and yearly INR 46.13. At the current price INR 53.53, the model implies a +16.23% upside to the monthly target and a -9.90% downside to the quarterly figure. The 12-month projection implies -13.82% from today. Forecasts are model-based projections and not guarantees. Traders should treat short-term momentum and the Feb 3, 2026 earnings release as the next catalysts.
Catalysts, sector context and key risks
Catalysts include the earnings announcement on Feb 3, 2026, export demand in the drug manufacturers sector, and any margin expansion from cost controls. The healthcare sector has underperformed recent months, with average sector P/E near 39.27, but defensive demand often lifts specialty generics. Key risks: stretched valuation (P/B 6.11), long receivables cycle with DSO 122.58 days, and thin free cash flow metrics. Regulatory or export disruption would hit revenues quickly given the company’s export focus. For recent market-context reading, see MarketBeat coverage on sector moves source.
Final Thoughts
MEDICO.BO stock has surfaced as a top pre-market gainer on Jan 24, 2026, driven by a 19.75% spike to INR 53.53 and a volume surge. Short-term momentum looks constructive, but technical oscillators show limited trend conviction. Our benchmarks show a mixed fundamental picture: healthy ROE at 18.35% and low leverage contrast with a high P/B 6.11 and P/E 35.89. Meyka AI’s model projects a near-term bullish scenario to INR 62.22 (implied +16.23%) but also flags lower quarterly and yearly targets at INR 48.23 and INR 46.13. Given the Feb 3, 2026 earnings catalyst and current valuation, the balanced stance is to monitor earnings and volume confirmation before adding exposure. Investors wanting upside exposure should consider staged entries with stops below recent support near INR 48.34. Meyka AI, an AI-powered market analysis platform, provides this data-driven frame to guide risk-aware decisions. Forecasts are model-based projections and not guarantees.
FAQs
What drove the pre-market jump in MEDICO.BO stock today?
The pre-market jump to INR 53.53 came on a 19.75% price rise and volume of 48,776 shares. Early buying outpaced average volume, suggesting short-term momentum. The Feb 3, 2026 earnings date and export demand in the specialty generics sector are likely catalysts.
What valuation metrics matter for MEDICO.BO analysis?
Key metrics: P/E 35.89, P/B 6.11, ROE 18.35%, net margin 6.61%, and current ratio 1.62. These show profitability but relatively high price multiples versus sector peers, increasing sensitivity to earnings.
What are realistic MEDICO.BO stock price targets?
Meyka AI’s model projects a monthly target of INR 62.22 (+16.23% vs INR 53.53). Quarterly model is INR 48.23 (-9.90%) and yearly is INR 46.13 (-13.82%). These are model projections, not guarantees.
Should investors buy MEDICO.BO after this pre-market move?
Given mixed technicals and stretched valuation, consider waiting for earnings confirmation on Feb 3, 2026, or buying in tranches with tight stops. The Meyka grade is B (HOLD), signalling caution alongside selective accumulation.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
